Accessibility Menu
InflaRx logo

InflaRx(NASDAQ) IFRX

Market Cap$300.48MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2017)-86%
5 Year-15%
1 Year+147%
1 Month+1%
$2.06
+0.74%
+0.01Today
After hours$2.06+$0.00 (+0.00%)
InflaRx last closing stock price
MetricPriceDate
Last closeUSD 2.042026-08-14
InflaRx stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+10.87%USD 1.842026-08-07
1 month+0.99%USD 2.022026-07-15
3 month-17.41%USD 2.472026-05-15
Year to date+101.98%USD 1.012025-12-31
1 year+146.59%USD 0.832025-08-14
3 year-40.87%USD 3.452023-08-15
5 year-15.35%USD 2.412021-08-13
Since inception-86.39%USD 14.992017-11-08

InflaRx Financials at a Glance

Market Cap

$300.48MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

-€10.10K

Net Income (TTM)

-€39.14M

EPS (TTM)

$0.00

P/E Ratio

-1.95

Dividend

$0.00

Beta (Volatility)

0.90 (Low)

Price

$2.06

Volume

556,996.717

Open

$2.04

Previous Close

$2.07

Daily Range

$2.03 - $2.10

52-Week Range

$0.80 - $2.95

Estimated Earnings Date

Nov 9, 2026

IFRX News

A flaming arrow moving up.

Why InflaRx Stock Skyrocketed This Week

Keith NoonanApr 7, 2023
nurse and doctors in masks discussing chart

Why Shares of InflaRx Are Soaring Wednesday

James HalleyApr 5, 2023

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About InflaRx

InflaRx N.V. is a biopharmaceutical company focused on developing therapies that target the complement system, an essential part of the immune system. The company aims to treat inflammatory diseases with unmet medical needs by developing innovative monoclonal antibodies.

Products and Services

Treatments targeting the complement component C5a to manage inflammation.

Monoclonal antibodies designed to precisely inhibit specific parts of the immune system.

Robust research and development pipeline focused on inflammatory diseases.

What Makes InflaRx N.V. Special

InflaRx stands out due to its focus on monoclonal antibodies that specifically target C5a, an inflammatory component, offering potentially safer and more effective treatments compared to broad-spectrum anti-inflammatory drugs.

Five Things You Need to Know

InflaRx specializes in targeting the complement system, a key part of the immune response.

The company's leading approach involves inhibiting C5a, aiming for improved treatment outcomes in inflammatory diseases.

InflaRx is led by industry veterans with extensive experience and a strategic vision for growth.

The growth strategy includes advancing drug candidates through clinical trials and expanding its research pipeline.

InflaRx seeks to address therapeutic gaps across multiple indications for long-term growth and stakeholder value.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

65

CEO

Niels Christoph Riedemann, MD, PhD

Website

www.inflarx.de

Headquarters

Jena, TH 07745, DE

IFRX Financials

Key Financial Metrics (TTM)

Gross Margin

48201.61%

Operating Margin

362271.47%

Net Income Margin

387532.08%

Return on Equity

-58.00%

Return on Capital

-113.72%

Return on Assets

-23.46%

Earnings Yield

-51.28%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$300.48MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

147.29M

Volume

557.00K

Avg. Volume

1.17M

Financials (TTM)

Gross Profit

-€4.87M

Operating Income

-€36.59M

EBITDA

-€38.79M

Operating Cash Flow

-€23.83M

Capital Expenditure

-€136.64K

Free Cash Flow

-€23.96M

Cash & ST Invst.

€158.45M

Total Debt

€832.83K

InflaRx Performance Analysis

InflaRx annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31EUR 0N/A
20232023-12-31EUR 68,207N/A
20242024-12-31EUR 179,332162.9%
20252025-12-31EUR 33,102-81.5%
InflaRx sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-39.6%
Q42025-12-31-242.4%
Q12026-03-31100.0%
Q22026-06-30N/A
InflaRx annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31EUR -0.70-45.9%
20232023-12-31EUR -0.8419.8%
20242024-12-31EUR -0.850.7%
20252025-12-31EUR -0.77-9.5%
InflaRx sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-3014.3%
Q42025-12-3122.2%
Q12026-03-3143.9%
Q22026-06-30-14.5%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

€0.00

-100.0%

Gross Profit

€0.00

+100.0%

Gross Margin

0.00%

N/A

Market Cap

$300.48MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$4.62M

N/A

Employees

65

N/A

Net Income

-€10.65M

+26.1%

EBITDA

-€10.63M

+25.1%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

€158.45M

+230.1%

Total Debt

€832.83K

+39.0%

Accounts Receivable

€1.55M

N/A

Inventory

€0.00

-100.0%

Long Term Debt

€560.26K

+174.8%

Short Term Debt

€272.57K

-31.0%

Return on Assets

-23.46%

N/A

Return on Invested Capital

-24.94%

N/A

Free Cash Flow

-€2.60M

+65.6%

Operating Cash Flow

-€2.57M

+66.0%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
STROSutro Biopharma, Inc.
$22.28+8.79%
CNTBConnect Biopharma Holdings Limited
$2.49-2.35%
KLRSKalaris Therapeutics Inc
$3.96-2.94%
IMAImageneBio Inc
$5.58-4.45%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$8.61-0.02%
SPCXSpace Exploration Technologies
$146.23+0.04%
IPSTIp Strategy
$7.39+2.36%
NVDANvidia
$225.01-0.00%

Questions About IFRX

What is the current price of InflaRx?

InflaRx is trading at $2.07 per share.

What is the 52-week range for InflaRx?

Over the past 52 weeks, InflaRx has traded between $0.80 and $2.95.

How much debt does InflaRx have?

As of the most recent reporting period, InflaRx reported total debt of €952.57K.

How much cash does InflaRx have on hand?

InflaRx reported €167.57M in cash and cash equivalents in its most recent financial results.

What is InflaRx’s dividend yield?

InflaRx does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services